Bio-Bridge Science (OTCBB: BGES) Presentation at the China Growth Conference Available via Webcast

Bio-Bridge Science, an Oak Brook Illinois-based biotech
company, announced today that its presentation at the China Growth
Conference in New York City is now available via webcast. Bio-Bridge
Science is one of 12 Chinese growth companies that appeared at the
China Growth Conference hosted by Adam Friedman Associates.
   Investors wishing to access the presentation should visit the Adam
Friedman Associates website at www.adam-friedman.com and click on the
China Growth Conference webcast button.

   About the Company:

   Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine, that is expected
to enter clinical trials early next year in China. The vaccine, based
on exclusive technology co-developed by CEO Liang Qiao, an associate
professor at Loyola University Chicago's Strich School of Medicine,
targets infection in mucosal tissues, the first type of tissue
attacked by HIV.
   The Chinese government, mindful of the rapid expansion of AIDS in
China has, through the "Green Mile Policy" acted to expedite the
approval of domestically produced HIV Vaccines and has dramatically
increased its spending on AIDS-related research. In accordance with
this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine
to market as early as 2008, far in advance of many other HIV Vaccines
currently in development. Bio-Bridge is currently constructing a new
$3 million state-of-the-art GMP research and manufacturing facility in
Beijing, which is expected to be completed by the end of this year.